Testosterone or Boldenone: What Is the Difference

Boldenone is often called testosterone's "milder relative," but this simplified formula conceals several fundamental differences: from legal status to metabolic pathways. The editorial team examined how these two substances actually differ from the standpoint of pharmacology and safety.

Origin and status of the two substances

Testosterone is the principal male sex hormone, synthesized in the Leydig cells of the testes and in small amounts in the adrenal glands. Its synthetic esters (enanthate, cypionate, undecanoate) are registered medicinal products with clear indications, primarily for treating confirmed hypogonadism in men.

Boldenone, or 1-dehydrotestosterone, is a synthetic androgen that, in the form of the undecylenate ester, was used mainly in veterinary medicine, particularly for horses. Boldenone products are not registered for humans in most countries, so clinical data on its effects in humans are far scarcer than for testosterone.

This difference in status has practical significance. For testosterone there are large randomized trials, clinical guidelines, and long-term safety observations. For boldenone, a considerable share of the information comes from veterinary work, animal studies, doping-sample analysis, and case reports.

Thus, in comparing these substances, we are effectively comparing a well-studied medicinal product with a substance whose evidence base for humans is fragmentary. This is worth keeping in mind whenever informal sources present boldenone as a "safer alternative."

Chemical structure: a single double bond

From a chemical standpoint, boldenone differs from testosterone only by one additional double bond between the first and second carbon atoms in ring A of the steroid skeleton. It is precisely this small change that determines most of the differences in how the molecule behaves in the body.

The double bond at position 1 changes the shape of ring A and its interaction with enzymes. This concerns primarily aromatase, which converts androgens into estrogens, and 5α-reductase, which converts testosterone into the more potent dihydrotestosterone (DHT).

Both substances act through the same androgen receptor. That is, the mechanism is fundamentally identical: binding to the receptor, transfer of the complex into the cell nucleus, and a change in the expression of genes that affect protein synthesis, erythropoiesis, lipid metabolism, and sexual characteristics.

It is important to understand that both testosterone and boldenone in pharmaceutical form are ester prodrugs. The ester determines the rate of release from the depot, and once it is cleaved off, the active molecule itself works in the blood.

Metabolism: estrogens and dihydro derivatives

Under the action of aromatase, testosterone is converted into estradiol. In men this estrogen is not a "by-product": it is needed for bone health, libido, and lipid metabolism. However, at supraphysiological androgen levels, excess estradiol can cause gynecomastia and fluid retention.

Boldenone is also a substrate for aromatase, but it is converted into estrogens more slowly. The end product, as with testosterone, is estradiol, though it is formed in smaller amounts. Therefore the claim that "boldenone produces no estrogenic effects" is incorrect: the risk is lower, but not zero.

The second difference concerns 5α-reductase. In the skin, hair follicles, and prostate, testosterone is converted into DHT, which enhances androgenic effects: acne, male-pattern baldness, prostate enlargement. Boldenone is also metabolized by 5α-reductase, but the metabolite formed is considered a weaker androgen than DHT.

It is precisely this that underlies the widespread notion that boldenone is "less androgenic." It has some pharmacological basis, but its quantitative estimates mostly come from old animal studies and cannot be transferred directly to humans.

Pharmacokinetics and duration of action

The duration of action is determined mainly by the ester. Testosterone is available in a wide range of forms — from the short propionate to the long undecanoate, which in replacement therapy is administered at intervals of several weeks. This gives the physician flexibility in tailoring the regimen to a particular patient.

On the market boldenone is represented almost exclusively by the undecylenate — an ester with a long chain. This form provides slow release and prolonged presence of the substance in the body, and hence a prolonged effect, including undesirable ones.

A practical consequence of a long ester is inertia. If side effects appear, the level of the substance in the blood declines slowly, and a person may feel the consequences for weeks. For this reason, in medical practice testosterone therapy is sometimes started with shorter forms or gels.

The long ester and slow metabolism of boldenone also affect the duration of its detectability in doping control. Boldenone metabolites are identified by modern mass spectrometry methods, and the substance itself is included in section S1 of the WADA Prohibited List.

Risk profile compared

The key risks of both substances are shared, since they are associated with activation of the androgen receptor at supraphysiological concentrations. These are suppression of one's own hormonal axis, changes in the lipid profile, increased hematocrit, and effects on the heart and psyche.

• Suppression of the hypothalamic-pituitary-gonadal axis— characteristic of both; prolonged reduction of one's own testosterone and impaired spermatogenesis are possible.
• Hematocrit— testosterone stimulates erythropoiesis in a dose-dependent manner; for boldenone, informal sources describe a similar or more pronounced effect, but controlled data for humans are scarce.
• Lipids— a reduction in HDL is characteristic of androgens in general, especially at supraphysiological levels.
• Estrogenic effects— more typical of testosterone; for boldenone they are less pronounced, but possible.
• Psyche— irritability, aggressiveness, and mood swings are described for androgens as a class.

A substantial difference lies in product quality. Testosterone is legally manufactured by pharmaceutical companies to GMP standards. Boldenone for humans usually comes from the illegal market, where concentration discrepancies, impurities, and sterility violations occur.

For women, both substances carry a risk of virilization — deepening of the voice, hirsutism, changes in the menstrual cycle. Some of these changes are irreversible. The common belief that boldenone "suits women" has no clinical evidence behind it.

Large reviews, in particular the scientific statement of the Endocrine Society, emphasize that long-term non-medical use of androgens is associated with cardiomyopathy, accelerated atherosclerosis, and psychiatric consequences. These data apply to the class as a whole, and there are no grounds to consider boldenone an exception.

Editorial conclusions

Testosterone and boldenone differ by one double bond, but this difference changes their metabolism: boldenone aromatizes more slowly and forms a weaker 5α-reduced metabolite.

At the same time, the shared mechanism of action through the androgen receptor also means shared key risks: suppression of the hormonal system, changes in blood and lipids, and strain on the heart.

The main practical difference is the level of evidence and quality control: testosterone is a well-studied medicinal product, whereas boldenone is not one for humans.

The editorial team also recommends reading our materials on hematocrit during androgen use, on aromatization and estrogen control, and on the tests for assessing hormonal status.

References

1. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
2. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996;42(7):1001–1020.
3. Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
4. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
5. Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
6. World Anti-Doping Agency. The Prohibited List. International Standard. Montreal: WADA; 2025.
7. Nieschlag E, Behre HM, Nieschlag S (eds). Testosterone: Action, Deficiency, Substitution. 4th ed. Cambridge University Press; 2012.